195 related articles for article (PubMed ID: 21747318)
1. Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.
Kim YS; Oh SH; Park KS; No H; Oh BJ; Kim SK; Jung HS; Kim JH; Lee MS; Lee MK; Kim KW
Pancreas; 2011 Aug; 40(6):855-60. PubMed ID: 21747318
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of beta-cell regeneration by islet transplantation after partial pancreatectomy in mice.
Jung HS; Ahn YR; Oh SH; Kim YS; No H; Lee MK; Kim KW
Transplantation; 2009 Aug; 88(3):354-9. PubMed ID: 19667937
[TBL] [Abstract][Full Text] [Related]
4. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
[TBL] [Abstract][Full Text] [Related]
5. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
6. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Akarte AS; Srinivasan BP; Gandhi S
J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.
Suarez-Pinzon WL; Rabinovitch A
Cell Transplant; 2011; 20(9):1343-9. PubMed ID: 21396168
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
9. Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.
Hou J; Zheng D; Fan K; Yu B; Xiao W; Ma J; Jin W; Tan Y; Wu J
Pharmacology; 2012; 90(3-4):177-82. PubMed ID: 22948814
[TBL] [Abstract][Full Text] [Related]
10. Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.
Yeom JA; Kim ES; Park HS; Ham DS; Sun C; Kim JW; Cho JH; Yoon KH
BMB Rep; 2011 Nov; 44(11):713-8. PubMed ID: 22118536
[TBL] [Abstract][Full Text] [Related]
11. 16,17-Dihydro-17b-hydroxy isomitraphylline alkaloid as an inhibitor of DPP-IV, and its effect on incretin hormone and β-cell proliferation in diabetic rat.
Shukla A; Srinivasan BP
Eur J Pharm Sci; 2012 Sep; 47(2):512-9. PubMed ID: 22820565
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.
Liang J; Leung KK; Lam SY; Leung PS
Diabetes Obes Metab; 2012 Sep; 14(9):842-51. PubMed ID: 22519909
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.
Samikannu B; Chen C; Lingwal N; Padmasekar M; Engel FB; Linn T
PLoS One; 2013; 8(12):e82639. PubMed ID: 24349326
[TBL] [Abstract][Full Text] [Related]
15. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
[TBL] [Abstract][Full Text] [Related]
16. Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
Han SJ; Choi SE; Kang Y; Jung JG; Yi SA; Kim HJ; Lee KW; Kim DJ
Diabetes Res Clin Pract; 2011 May; 92(2):213-22. PubMed ID: 21345512
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
[TBL] [Abstract][Full Text] [Related]
18. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2009 Mar; 58(3):641-51. PubMed ID: 19073764
[TBL] [Abstract][Full Text] [Related]
20. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]